| Literature DB >> 24776724 |
Robert D Wojtyczka1, Kamila Orlewska2, Małgorzata Kępa3, Danuta Idzik4, Arkadiusz Dziedzic5, Tomasz Mularz6, Michał Krawczyk3, Maria Miklasińska7, Tomasz J Wąsik8.
Abstract
The hospital environment microflora comprise a wide variety of microorganisms which are more or less pathogenic and where staphylococci are one of the most common types. The aim of the presented study was to evaluate the prevalence of the biofilm forming coagulase-negative staphylococci (CoNS) in a hospital environment as a risk factor for nosocomial infections. Among 122 isolated and tested strains of CoNS the most frequent were: S. epidermidis-32 strains, S. haemolyticus-31 strains, S. capitis subsp. capitis- 21 strains, S. hominis-11 strains, S. cohnii subsp. cohnii-nine strains. In case of CoNS, the main molecule responsible for intercellular adhesion is a polysaccharide intercellular adhesin (PIA), encoded on the ica gene operon. The analysis revealed the presence of the icaADBC operon genes in 46.88% of S. epidermidis isolates. IcaA and icaD were present in 34.38% and 28.13% of strains respectively while IcaC gene was present in 37.50% of strains. IcaB gene was found in 21.88% of S. epidermidis strains. In 15 (63%) strains all icaADBC operon genes were observed. The assessment of antibacterial drugs susceptibility demonstrated that analyzed CoNS strains were highly resistant to macrolides and lincosamides and more sensitive to rifampicin and linezolid. Our data indicates that the hospital environment can be colonized by biofilm forming coagulase-negative staphylococci and transmission of these strains can cause an increased risk of serious nosocomial infections.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24776724 PMCID: PMC4053877 DOI: 10.3390/ijerph110504619
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
The number/percentage of CoNS strains susceptible to selected chemotherapeutics.
| Strain (No. of Strains) | a FOX | a E | a DA | a T | a C | a CIP | a CN | a RIF | a LNZ | a SXT |
|---|---|---|---|---|---|---|---|---|---|---|
| 25/78.1 | 18/56.3 | 26/81.3 | 25/78.1 | 32/100 | 32/100 | 31/96.9 | 32/100 | 31/96.9 | 23/71.9 | |
| 26/83.9 | 14/45.2 | 19/61.3 | 26/83.9 | 25/80.6 | 27/87.1 | 28/90.3 | 31/100 | 31/100 | 18/58.1 | |
| 17/81 | 9/42.9 | 15/71.4 | 19/90.5 | 21/100 | 10/47.6 | 10/41.6 | 19/90.5 | 21/100 | 17/81 | |
| 10/90.9 | 4/36.4 | 9/81.8 | 6/54.5 | 9/81.8 | 11/100 | 11/100 | 11/100 | 11/100 | 8/72.7 | |
| 7/77.8 | 5/55.6 | 5/55.6 | 5/55.6 | 9/100 | 9/100 | 9/100 | 9/100 | 9/100 | 5/55.6 | |
| 5/100 | 1/20 | 4/80 | 5/100 | 5/100 | 5/100 | 5/100 | 5/100 | 5/100 | 3/60 | |
| 4/100 | 2/50 | 3/75 | 1/25 | 3/75 | 4/100 | 4/100 | 4/100 | 4/100 | 4/100 | |
| 3/75 | 1/25 | 1/25 | 3/75 | 3/75 | 4/100 | 4/100 | 4/100 | 4/100 | 3/75 | |
| 2/100 | 0/0 | 1/50 | 1/50 | 2/100 | 2/100 | 2/100 | 2/100 | 2/100 | 1/50 | |
| 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | |
| 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 0/0 | |
| 1/100 | 0/0 | 1/100 | 0/0 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | 1/100 | |
| Total (122)/% | 10/83.6 | 56/45.9 | 86/70.5 | 93/76.2 | 112/91.8 | 107/87.7 | 107/87.7 | 120/98.4 | 121/99.2 | 84/68.9 |
a FOX—cefoxitin, E—erythromycin, DA—clindamycin, T—tetracycline, C—chloramphenicol, CIP—ciprofloxacin, CN—gentamicin, RIF—rifampicin, LIN—linezolid and SXT trimethoprim/ sulphamethoxazole.
Figure 1The proportion of susceptible and resistant CoNS strains to the tested chemotherapeutics.
Figure 2The proportion of susceptible and resistant S. epidermidis strains to the tested chemotherapeutics.
Assessment of biofilm formation ability of CoNS strains determined by CRA and TCP methods.
| Strain (No. of strains) | No (%) of Positive Strains, CRA Method | No (%) of Positive Strains, TCP Method OD > 0.17,—Strong Biofilm Production | No (%) of Positive Strains, TCP Method 0.11 > OD >0.16—Weak Biofilm Production |
|---|---|---|---|
| 0 | 9 (28.1) | 3 (9.4) | |
| 1 (3.2) | 1 (3.2) | 3 (3.2) | |
| 3 (14.3) | 0 | 1 (4.8) | |
| 1 (9.1) | 0 | 2 (18.2) | |
| 2 (22.2) | 0 | 0 | |
| 0 | 0 | 0 | |
| 1 (25) | 1 (25) | 1 (25) | |
| 0 | 0 | 1 (25) | |
| 0 | 1 (50) | 1 (50) | |
| 0 | 0 | 0 | |
| 1 (100) | 0 | 0 | |
| 0 | 0 | 1 (100) | |
| Total: (122) | 9 (7.4) | 12 (9.8) | 13 (10.7) |
Figure 3Detection of operon icaADBC genes in Staphylococcus epidermidis strains. (A) PCR results with primer for icaA, positive probe—the presence of the 814-bp product; (B) PCR results with primer for icaB and icaD, positive probe—the presence of the 526-bp product to icaB and 371-bp product to icaD; and (C) PCR results with primer for icaC genes, positive probe—the presence of the 989-bp product. Line 1—molecular size maker 100-1000-bp, line 2-9 different S. epidermidis strains.
S. epidermidis strains susceptibility to chemotherapeutics with correlation to phenotypic biofilm production ability.
| a FOX | a E | a DA | a T | a C | a CIP | a CN | a RIF | a LNZ | a SXT | |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 18 | 26 | 25 | 32 | 32 | 31 | 32 | 31 | 23 | |
| 78.1% | 56.3% | 81.3% | 78.1% | 100% | 100% | 96.9% | 100% | 96.9% | 71.9% | |
| 9 | 6 | 9 | 9 | 12 | 12 | 11 | 12 | 11 | 10 | |
| 75% | 50% | 75% | 75% | 100% | 100% | 91.7% | 100% | 91.7% | 83.3% | |
| 16 | 12 | 17 | 16 | 20 | 20 | 20 | 20 | 20 | 13 | |
| 80% | 60% | 85% | 80% | 100% | 100% | 100% | 100% | 100% | 65% | |
|
| 1.000 | 0.718 | 0.647 | 0.535 | c NA | NA | 0.375 | NA | 0.375 | 0.205 |
a FOX—cefoxitin, E—erythromycin, DA—clindamycin, T—tetracycline, C—chloramphenicol, CIP—ciprofloxacin, CN—gentamicin, RIF—rifampicin, LIN—linezolid and SXT trimethoprim/ sulphamethoxazole b p: the two-sided Fisher’s exact test for biofilm forming strains vs. non biofilm forming strains; all presented P values are two-sided, p ≤ 0.05 was considered as statistically significant. c NA—not applicable.